| 0 (0%) | 10-15 12:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 108.91 | 1-year : | 127.21 |
| Resists | First : | 93.24 | Second : | 108.91 |
| Pivot price | 69.28  |
|||
| Supports | First : | 71.17 |
Second : | 57.52 |
| MAs | MA(5) : | 77.36 |
MA(20) : | 67.95 |
| MA(100) : | 57.31 |
MA(250) : | 48.8 |
|
| MACD | MACD : | 4.5 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 49.5 |
D(3) : | 60.7 |
| RSI | RSI(14): 63.4 |
|||
| 52-week | High : | 93.24 | Low : | 33.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PTGX ] has closed below upper band by 23.0%. Bollinger Bands are 218.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 78.52 - 79.05 | 79.05 - 79.49 |
| Low: | 75 - 75.51 | 75.51 - 75.93 |
| Close: | 76.19 - 77.02 | 77.02 - 77.71 |
Mon, 13 Oct 2025
Noteworthy Monday Option Activity: JANX, AI, PTGX - Nasdaq
Mon, 13 Oct 2025
Protagonist Therapeutics falls amid a report J&J deal price may be lower (PTGX:NASDAQ) - Seeking Alpha
Mon, 13 Oct 2025
Street View: Protagonist's 'main character' energy draws J&J to potential takeover talks - TradingView
Sat, 11 Oct 2025
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues - simplywall.st
Sat, 11 Oct 2025
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High - Here's What Happened - MarketBeat
Fri, 10 Oct 2025
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 62 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 116.3 (%) |
| Shares Short | 6,640 (K) |
| Shares Short P.Month | 6,850 (K) |
| EPS | 0.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.76 |
| Profit Margin | 24.8 % |
| Operating Margin | -758.1 % |
| Return on Assets (ttm) | 2.2 % |
| Return on Equity (ttm) | 8.6 % |
| Qtrly Rev. Growth | 33 % |
| Gross Profit (p.s.) | 3.36 |
| Sales Per Share | 3.36 |
| EBITDA (p.s.) | 0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 40 (M) |
| Levered Free Cash Flow | 26 (M) |
| PE Ratio | 105.02 |
| PEG Ratio | 0 |
| Price to Book value | 7.12 |
| Price to Sales | 22.8 |
| Price to Cash Flow | 120.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|